Drugs / silevertinib
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06072586 | Oct 2023 → Dec 2026 expected | glioblastoma | St. Joseph's Hospital and Medical Center, Phoenix | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05256290 | Mar 2022 → Nov 2025 overdue | non-small cell squamous lung carcinoma | Black Diamond Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07326566 | May 2026 → Nov 2028 expected | brain cancer, glioblastoma | Black Diamond Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | silevertinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05256290 ↗ |
| Known as | BDTX-1535 | “designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of silevertinib (BDTX-1535)” NCT05256290 ↗ |
| Action | Inhibit | “4th generation irreversible brain penetrant EGFR MasterKey inhibitor” NCT05256290 ↗ |
| Route | Oral | “All patients will self-administer silevertinib (BDTX-1535) monotherapy by mouth” NCT05256290 ↗ |
| Target | EGFR | “targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC” NCT05256290 ↗ |